Verona Pharma plc
VRNA
Classificação em ações
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Preço da ação
$106.91
Última sincronização: 2025-10-07
Valor de mercado
$9.09B
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
GB
Negociar Verona Pharma plc (VRNA)
Categoria
Healthcare
EPS de Verona Pharma plc (VRNA)
EPS em June 2025 TTM: $-0.77
De acordo com os últimos relatórios financeiros e o preço das ações da Verona Pharma plc, o EPS atual da empresa (TTM) é $-0.77. No final de 2023, a empresa teve um EPS de $-0.54, uma diminuição em relação a ao EPS de 2022, que foi de $-0.86.
Histórico de EPS da Verona Pharma plc de 2005 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-0.77 | -54.71% |
| 2024 | $-1.70 | 214.81% |
| 2023 | $-0.54 | -37.21% |
| 2022 | $-0.86 | 24.64% |
| 2021 | $-0.69 | -52.41% |
| 2020 | $-1.45 | -53.07% |
| 2019 | $-3.09 | 60.65% |
| 2018 | $-1.92 | -23.89% |
| 2017 | $-2.53 | 70.63% |
| 2016 | $-1.48 | -66.16% |
| 2015 | $-4.38 | 121.20% |
| 2014 | $-1.98 | -59.64% |
| 2013 | $-4.90 | 43.91% |
| 2012 | $-3.41 | -36.19% |
| 2011 | $-5.34 | -10.68% |
| 2010 | $-5.98 | 9.91% |
| 2009 | $-5.44 | 41.09% |
| 2008 | $-3.85 | -38.00% |
| 2007 | $-6.22 | 108.58% |
| 2006 | $-2.98 | -3,065.67% |
| 2005 | $0.10 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -2,349.35% |
US
|
|
| $-7.98 | 936.36% |
US
|
|
| $-5.29 | 587.01% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,702.60% |
NL
|
